Multi-omics Profiling of Relapsed Extranodal Natural Killer (NK)/T-cell Lymphoma
NCT07920757, Active not recruiting, Fujian Medical University Union Hospital
Trial 8
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Multi-omics Profiling of Relapsed Extranodal Natural Killer (NK)/T-cell Lymphoma | ClinicalTrials.gov |
| NCT number | NCT07920757 | ClinicalTrials.gov |
| Status | Active not recruiting | ClinicalTrials.gov |
| Enrollment | 50 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Fujian Medical University Union Hospital | ClinicalTrials.gov |
| Conditions | Extranodal NK/T-cell Lymphoma, Nasal Type | ClinicalTrials.gov |
| First posted | 2026-11-06 | ClinicalTrials.gov |
| Last updated | 2026-11-06 | ClinicalTrials.gov |
Registered outcomes 6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Composition and transcriptional states of immune and stromal cell populations in ENKTCL tumour tissue | Baseline (pre-treatment) and relapse (up to 36 months after diagnosis); assessed retrospectively | Cell-type composition, activation and exhaustion states of T, NK, B and myeloid populations and of stromal subsets, determined by single-cell RNA sequencing of tumour tissue. | ClinicalTrials.gov |
| Primary | Clonal architecture of T-cell and B-cell receptor repertoires | Baseline and relapse (up to 36 months after diagnosis); assessed retrospectively | Clonal diversity and the distribution of expanded clones across transcriptional cell states, determined by paired T-cell and B-cell receptor repertoire sequencing. | ClinicalTrials.gov |
| Secondary | Somatic genomic alterations, including chromosome 6q copy-number loss | Baseline, assessed retrospectively | Somatic mutations and copy-number alterations determined by whole-exome sequencing of tumour tissue. | ClinicalTrials.gov |
| Secondary | Spatial organisation of tumour and immune compartments | Baseline and relapse (up to 36 months after diagnosis); assessed retrospectively | Spatial distribution of malignant, immune and stromal compartments in archival tissue, determined by spatial transcriptomics and multiplex imaging. | ClinicalTrials.gov |
| Secondary | Correlation of baseline immune and stromal features with response to PD-1 or PD-L1 blockade | Baseline (pre-treatment) through study completion, an average of 36 months | Correlation between baseline immune and stromal features in tumour tissue, expressed as the percentage of cluster of differentiation 8 (CD8)-positive T cells, NK cells, B cells and plasma cells among all cells and as their spatial density (cells per mm2), measured by single-cell RNA sequencing and spatial transcriptomics; and objective response to PD-1 or PD-L1 blockade, expressed as the percentage of patients achieving a complete or partial response by RECIST 1.1 or LYRIC criteria. | ClinicalTrials.gov |
| Secondary | Correlation of baseline immune and stromal features with relapse site and pattern | Baseline (pre-treatment) through study completion, an average of 36 months | Correlation between baseline immune and stromal features in tumour tissue, expressed as the percentage of T cells, NK cells, B cells and plasma cells among all cells, measured by single-cell RNA sequencing; and relapse site and pattern, expressed as the percentage of patients with local, regional or distant relapse classified from imaging and clinical records. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)